Literature DB >> 22912388

Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?

Adam S Crystal1, Alice T Shaw.   

Abstract

Anaplastic lymphoma kinase (ALK) gene rearrangements are found in approximately 5% of non-small cell lung carcinoma patients and confer sensitivity to ALK inhibitors such as crizotinib. The particular ALK fusion expressed may have an impact on protein stability and sensitivity to crizotinib, and this may underlie the heterogeneity in responses observed in the clinic. ©2012 AACR.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22912388     DOI： 10.1158/1078-0432.CCR-12-1952

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  6 in total

1.  Anchored multiplex PCR for targeted next-generation sequencing.

Authors:  Zongli Zheng; Matthew Liebers; Boryana Zhelyazkova; Yi Cao; Divya Panditi; Kerry D Lynch; Juxiang Chen; Hayley E Robinson; Hyo Sup Shim; Juliann Chmielecki; William Pao; Jeffrey A Engelman; A John Iafrate; Long Phi Le
Journal:  Nat Med       Date:  2014-11-10       Impact factor: 53.440

Review 2.  Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer.

Authors:  Mukesh Kumar; Vinicius Ernani; Taofeek K Owonikoko
Journal:  Mol Aspects Med       Date:  2015-07-14

3.  The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.

Authors:  Lien Tembuyser; Véronique Tack; Karen Zwaenepoel; Patrick Pauwels; Keith Miller; Lukas Bubendorf; Keith Kerr; Ed Schuuring; Erik Thunnissen; Elisabeth M C Dequeker
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

4.  Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology.

Authors:  Adriane F Evangelista; Maicon F Zanon; Adriana Cruvinel Carloni; Flávia E de Paula; Mariana Andozia Morini; Maressa Ferreira-Neto; Iberê Cauduro Soares; Jose Elias Miziara; Pedro de Marchi; Cristovam Scapulatempo-Neto; Rui M Reis
Journal:  BMC Pulm Med       Date:  2017-05-26       Impact factor: 3.317

5.  Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis.

Authors:  Mukesh Bansal; Jing He; Michael Peyton; Manjunath Kustagi; Archana Iyer; Michael Comb; Michael White; John D Minna; Andrea Califano
Journal:  PLoS One       Date:  2019-01-07       Impact factor: 3.240

6.  Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non-Small Cell Lung Cancer.

Authors:  Richard A Blidner; Brian C Haynes; Stephen Hyter; Sarah Schmitt; Ziyan Y Pessetto; Andrew K Godwin; Dan Su; Patrick Hurban; Léon C van Kempen; Maria L Aguirre; Shobha Gokul; Robyn D Cardwell; Gary J Latham
Journal:  J Mol Diagn       Date:  2018-12-04       Impact factor: 5.341
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.